Skip to main content
Premium Trial:

Request an Annual Quote

Incyte Demands Cake, Bite

NEW YORK, Dec. 16 - Incyte Genomics will change its name next year to Incyte Corporation.


The company, which changed its name to Incyte Genomics from Incyte Pharmaceuticals two years ago, said its latest re-christening is designed to reflect a "broader mission" as a company devoted to discovering drugs and selling discovery tools.


"This decision was driven by the desire to unify our genomic and proteomic information business, intellectual property and rapidly growing drug discovery organization under the Incyte name," CEO Paul Friedman said without irony. "We believe the name change will help position the company better among our customers, collaborators, stockholders and employees as an emerging drug discovery company."


Incyte said it also will "launch a new graphic look" and web site next year "to reflect the new corporate identity."


The name change is the latest step in Incyte's slow metamorphosis into a drug company--in this case, a drug company that also happens to sell tools.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more